# How to make a JAK inhibitor "gut-restricted"
### A one-page explainer for a non-technical audience

## The problem in one sentence

JAK inhibitors are pills that switch off an inflammation signal called **JAK-STAT**. They work well for gut diseases like celiac and EoE — but because that same signal is used all over the body, a normal JAK pill that spreads into the bloodstream can cause serious side-effects (infections, blood clots). The whole idea of a **gut-restricted** JAK inhibitor is to keep the drug working *in the gut wall*, where the disease is, and *out of the bloodstream*, where the side-effects come from.

## The one picture to remember

Think of the gut as three layers stacked on top of each other:

1. **The gut lumen** — the hollow inside of the intestine, where a swallowed pill dissolves.
2. **The gut wall lining** — the thin sheet of cells right underneath, which is the tissue that is actually *sick* in celiac and EoE.
3. **The bloodstream** — everything past the gut wall, i.e. the rest of the body.

A gut-restricted drug is engineered so it can get *into layer 2* (to do its job) but **cannot cross out of layer 2 into layer 3**. You get the full treatment effect in the sick tissue and almost nothing anywhere else.

## How chemists actually achieve this

Absorption — a molecule crossing from the gut into the blood — depends on simple physical properties of the molecule. To *stop* absorption on purpose, you build the drug with the opposite of the usual "easily absorbed" features:

1. **Make it too "wet" to cross a greasy membrane.** Cell membranes are oily. A molecule loaded with water-loving groups clings to water and can't slip through the oily barrier. Chemists deliberately add these groups so the drug stays in the watery gut.
2. **Give it a permanent electrical charge.** A charged molecule physically cannot pass through the oily core of a membrane. Building in a charge (or a molecule that carries both a plus and a minus at the same time) is one of the most reliable ways to trap a drug in the gut.
3. **Make it a target for the gut's "bouncer" pumps.** The gut lining has pumps (P-glycoprotein) whose job is to shove foreign molecules back into the gut. Design the drug to be something these pumps grab, and any small amount that starts to sneak across gets kicked right back.
4. **(Backup tactic) Make it self-destruct if it does escape.** You can add a chemical "fuse" that the liver snips within minutes, so even the little that leaks into the blood is destroyed before it can act. This is exactly how the gut steroid **budesonide** already works.

The clever part: the drug still has to get *inside* the sick cells of the gut wall to reach JAK — it just must not travel all the way *through* the wall into the blood. Because a swallowed pill delivers a huge amount of drug right onto the gut lining, plenty gets into those cells by sheer concentration, while the amount that makes it to the bloodstream stays tiny.

## The real-world example

**Izencitinib (TD-1473)** is a JAK inhibitor that was deliberately designed this way for inflammatory bowel disease. Its trial results have been **mixed** — which teaches the one honest limitation below.

## The one catch you should know

Gut-restriction works beautifully **when the sick target sits near the surface** of the gut wall — which is true for celiac and EoE, where the damage is in the surface lining. It works *less* well if the disease reaches deep below the surface (like the deep, tunneling inflammation of some Crohn's disease), because a drug engineered to stay near the surface may not reach that far down. So the rule of thumb is: **the closer the disease is to the gut surface, the better gut-restriction works** — and for the two diseases in this project, it's a strong fit.

## Why this matters for celiac and EoE specifically

- **Celiac:** our own data pointed to the **IFN-γ → JAK → STAT1** signal as the main driver of the villous (gut-surface) damage. A gut-restricted JAK inhibitor would shut that down right where the villi are being destroyed — without dosing the whole body.
- **EoE:** the disease is driven by an **IL-13/IL-4 → JAK → STAT6** signal in the esophageal lining. A locally-acting version is the alternative to the systemic biologic (dupilumab) that gave the index-case patient eye-inflammation side-effects.

---
*Companion to the gut-restricted therapeutics landscape review. Schematic: gut_restricted_jak_schematic.png.*